A 28-year-old male presents with a 5-year history of progressive bone pain, short stature (height 155 cm), blue sclerae, and recurrent fractures from minor trauma. Serum alkaline phosphatase is elevated at 120 U/L (normal: 30–120). Serum calcium and phosphate are normal. Which investigation is most specific for confirming osteogenesis imperfecta?

Explanation

## Diagnostic Approach to Osteogenesis Imperfecta ### Clinical Presentation The patient presents with classic features of OI: blue sclerae (due to thin sclera allowing visualization of underlying choroid), recurrent fractures from minor trauma, short stature, and bone pain. Elevated alkaline phosphatase reflects increased bone turnover. ### Investigation of Choice: Genetic Sequencing **Key Point:** Genetic sequencing for COL1A1 or COL1A2 mutations is the gold standard confirmatory test for osteogenesis imperfecta. These genes encode the α1 and α2 chains of type I collagen, which comprises ~90% of organic bone matrix. **High-Yield:** Type I collagen is the primary structural protein in bone, skin, tendons, and sclera. Mutations cause defective collagen synthesis, leading to poor bone quality (not just quantity), increased fragility, and characteristic skeletal and extraskeletal features. ### Why Genetic Sequencing is Superior | Investigation | Sensitivity | Specificity | Clinical Use | |---|---|---|---| | **Genetic sequencing (COL1A1/COL1A2)** | ~90% in OI | Definitive | Gold standard; enables classification, prognosis, and genetic counseling | | DEXA BMD | Variable | Low | Measures bone quantity, not quality; many OI patients have normal BMD despite fractures | | Alkaline phosphatase | Non-specific | Low | Reflects bone turnover; elevated in many conditions (Paget disease, hyperparathyroidism, healing fractures) | | Bone biopsy | Supportive | Moderate | Shows abnormal bone microarchitecture but not diagnostic; invasive | ### Clinical Pearl **Warning:** DEXA BMD may be normal or even high in OI despite severe fracture risk. This is because OI is primarily a **collagen quality disorder**, not a quantity disorder. The bone is biochemically defective (poor collagen cross-linking, abnormal mineralization), not simply osteopenic. ### Mnemonic: OI Classification by COL1A1/COL1A2 Severity **Type I** (mild, autosomal dominant): Missense mutations, normal stature, blue sclerae, few fractures. **Type II** (perinatal lethal): Frameshift/nonsense mutations, severe skeletal deformity, intrauterine fractures. **Type III** (progressive deforming): Frameshift mutations, severe deformity, progressive kyphoscoliosis. **Type IV** (moderate): Missense mutations, normal sclerae, moderate fractures. ## Why Other Options Are Incorrect **DEXA BMD measurement:** While it quantifies bone mineral density, it does not assess bone quality. Many OI patients have normal or even elevated BMD but suffer pathological fractures due to defective collagen. DEXA is useful for monitoring treatment response but is not diagnostic for OI. **Serum alkaline phosphatase and bone-specific alkaline phosphatase:** These are non-specific markers of bone turnover. Elevated levels occur in fracture healing, Paget disease, hyperparathyroidism, and many other conditions. They reflect metabolic activity but do not confirm OI or identify the molecular defect. **Bone biopsy with histomorphometry:** While it may show abnormal bone microarchitecture (e.g., thin trabeculae, poor mineralization), it is invasive, non-specific, and does not identify the genetic mutation. It is rarely used in modern practice for OI diagnosis.